Curcuminoids from Curcuma longa in the fight against cancer and age related disorders

Australian Journal of Medical Herbalism

Volumn 20, Issue 2, 2008, Pages 57-63

  Badmaev, Vladimir ^a   Aggarwal, Bharat B ^b   Fiala, Milan ^c   Majeed, Muhammed ^a   Golombick, T ^d   Diamond, T ^d  

^a SABINSA CORPORATION   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48249154595     PISSN: 10338330     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. 2005. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 15:11(20);7490-8.
2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. 2007. Curcumin: the Indian solid gold. Adv Exp Med Biol 595;1-75.
3. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. 2007. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72(1);29-39.
4. Bhandarkar SS, Arbiser JL. 2007. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 595;185-95. Review.
5. Cheng AL, Hsu CH, Lin JK et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21; 2895-900.
6. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM. 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4(8); 1035-8. Epub Jun 6.
7. Dhillon N, Aggarwal BB, Newman R, Wolff R, Kunnumakkara AB, Abbruzzese J et al. 2007. Phase II Trial of Curcumin, an NF-kappaB Inhibitor, in Patients with Advanced Pancreatic Cancer (submitted to Clin Can Res 2007).
8. Dorai T, Dutcher JP, Dempster DW, Wiernik PH. 2004. Therapeutic potential of curcumin in prostate cancer-V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 15:60(1);1-17.
9. Fiala M, Cribbs DH, Rosenthal M, Bernard G. 2007a. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis 11 (4);457-63.
10. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM. 2007b. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimers disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 31:104(31);l 2849-54. Epub Jul 24.
11. Garg A, Aggarwal BB. 2002. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16(6);1053-68. Review.
12. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA. 2003. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15(6):405-11. Review.
13. Gautam SC, Gao X, Dulchavsky S. 2007. Immunomodulation by curcumin. Adv Exp Med Biol 595;321-41. Review.
14. Hong RL, Spohn WH, Hung MC. 1999. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5(7); 1884-91.
15. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL et al. 2001. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 1:61(3);1058-64.
16. Kamat AM, Sethi G, Aggarwal BB. 2007. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6(3); 1022-30.
17. Kiran MS, Kumar VB, Viji RI, Sherin GT, Rajasekharan KN, Sudhakaran PR. 2008. Opposing effects of curcuminoids on serum stimulated and unstimulated angiogenic response. J Cell Physiol 215(1);251-64.
18. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. 2007. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 15:67(8); 3853-61.
19. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, Krishnan S. 2008. Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to γ-Radiation by Targeting NF-κB-Regulated Gene Products. Clin Cancer Res (in press).
20. Kurd SK, Smith N, Vanvoorhees A, Troxel AB, Badmaev V, Seykora JT, Gelfand JIM. 2008. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol. Feb 2 [Eupub ahead of print].
21. Kuttan G, Kumar KB, Guruvayoorappan C, Kuttan R. 2007. Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv Exp Med Biol 595; 173-84. Review.
22. Kyle RA, Rajkumar SV. 2005. Monoclonal gammopathies of undetermined significance. Best Prac & Res Clin Haematol 18(4);689-707.
23. Lao CD, Demierre MF, Sondak VK. 2006a. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 6(11);1559-68. Review.
24. Lao CD, Ruffin MT, Brenner DE. 2006b. Dose escalation of curcuminoid formulation. BMC Complement Altern Med 17:6;10.
25. Li L, Braiteh FS, Kurzrock R. 2005. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104;1322-31.
26. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN et al. 2007. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 1: 13(11);3423-30.
27. McKellar G, Madhok R, Singh G. 2007. The problem with NSAIDs: what data to believe? Curr Pain Headache Rep 11(6);423-7. Review.
28. Mehta K, Pantazis P, McQueen T, Aggarwal BB. 1997. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8(5);470-81.
29. Ohshima H, Tazawa H, Sylla BS, Sawa T. 2005. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 11:591(1-2);110-22. Epub Aug 3.
30. Poma P, Notarbartolo M, Labbozzetta M, Maurici A, Carina V, Alaimo A et al. 2007. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis. Int J Mol Med 20(3);329-35.
31. Rao CV. 2007. Regulation of COX and LOX by curcumin. Adv Exp Med Biol 595;213-26. Review.
32. Raza A, Lagmay P, Mehdi M, Mumtaz M, Upadhyay R, Butt A, Ali T, Galili N. 2007. Saint Vincent's Comprehensive Cancer Center, New York, NY, University of Massachusetts Medical Center, Worcester. Multi-lineage response to a combination of gingerol and curcumin in low risk myelodysplastic syndromes (MDS). (Abstract prepared for publication).
33. Ridker PM, Hennekens CH, Buring JE, Rifai N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 23:342(12);836-43.
34. Ringman JIM, Cole G, Teng E, Badmaev V, Bardens J, Frautschy S et al. 2008. Oral Curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a 24-Week Study. UCLA Department of Neurology Kagan Alzheimer's Disease Treatment Development Program UCLA Alzheimer's Disease Center. LA 90095-722. (Abstract prepared for publication).
35. Sandur SK, Pancley MK, Sung B, Ahn KS, Murakami A, Sethi G et al. 2007. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogen 28(8); 1765-73.
36. Santangelo C, Varl R, Scazzocchio B, Di Benedetto R, Filesi C, Masella R. 2007. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita 43(4);394-405.
37. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt FIR, et al. 2004. Oncology Department, University of Leicester, Leicester; Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance. Clin Cancer Res 10;6847-54.
38. Sharma RA, McLelland HR, Hill KA et al. 2007. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7;1894-900.
39. Shishodia S, Sethi G, Aggarwal BB. 2005. Curcumin: getting back to the roots. Ann N Y Acad Sci. 1056;206-17.
40. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. 2004. Nonsteroidal anti inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 9:23(57);9247-58.
41. Telang N, Katdare M. 2007. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer. Oncol Rep 17(4);909-14.
42. Vadhan-Raj S, Weber D, Giralt S, Alexanian R, Thomas S, Zhou X et al. 2007. Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: Results of a phase1/2 study. Am Soc Hematol.
43. Zhang L, Fiala M, Cashman J, Sayrec J, Espinosa A, Mahaniana M et al. 2006. Dept of Medicine, Greater LA VA Medical Center and UCLA School of Medicine, Los Angeles, CA 90095, Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients. J Alzheimer's Dis 10; 1-7.